Yvonne  Greenstreet net worth and biography

Yvonne Greenstreet Biography and Net Worth

Dr. Yvonne Greenstreet joined Alnylam in 2016 as Chief Operating Officer and was promoted to President and COO in 2020. Yvonne has more than 25 years of experience in the Biopharmaceutical industry, driving strategy and innovation, bringing transformative medicines to patients, and building successful businesses in the US, Europe and globally.

Between 2011 and 2013, Yvonne was Senior Vice President and Head of Medicines Development at Pfizer serving on the executive team leading a rapidly growing $16bn division. Prior to Pfizer, she was at GlaxoSmithKline plc for 18 years, where she was Senior Vice President and Chief of Strategy for Research and Development. Yvonne had previously been in various positions of increasing responsibility at GSK, including Senior Vice President for Medicines Development and Chief Medical Officer for Europe.

Yvonne trained as a physician and earned her medical degree (MBChB) from The University of Leeds in the UK. She also holds an MBA from INSEAD Business school in France. Dr. Greenstreet serves on the board of directors of Pacira Pharmaceuticals and American Funds. Additionally, she is in the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and is a member of the Discovery Council of Harvard Medical School.

What is Yvonne Greenstreet's net worth?

The estimated net worth of Yvonne Greenstreet is at least $5.99 million as of August 4th, 2023. Dr. Greenstreet owns 35,216 shares of Alnylam Pharmaceuticals stock worth more than $5,988,129 as of December 9th. This net worth estimate does not reflect any other assets that Dr. Greenstreet may own. Additionally, Dr. Greenstreet receives a salary of $2,090,000.00 as COO at Alnylam Pharmaceuticals. Learn More about Yvonne Greenstreet's net worth.

How old is Yvonne Greenstreet?

Dr. Greenstreet is currently 60 years old. There are 5 older executives and no younger executives at Alnylam Pharmaceuticals. Learn More on Yvonne Greenstreet's age.

What is Yvonne Greenstreet's salary?

As the COO of Alnylam Pharmaceuticals, Inc., Dr. Greenstreet earns $2,090,000.00 per year. Learn More on Yvonne Greenstreet's salary.

How do I contact Yvonne Greenstreet?

The corporate mailing address for Dr. Greenstreet and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Yvonne Greenstreet's contact information.

Has Yvonne Greenstreet been buying or selling shares of Alnylam Pharmaceuticals?

Yvonne Greenstreet has not been actively trading shares of Alnylam Pharmaceuticals over the course of the past ninety days. Most recently, Yvonne Greenstreet sold 4,057 shares of the business's stock in a transaction on Friday, August 4th. The shares were sold at an average price of $185.85, for a transaction totalling $753,993.45. Following the completion of the sale, the chief executive officer now directly owns 35,216 shares of the company's stock, valued at $6,544,893.60. Learn More on Yvonne Greenstreet's trading history.

Who are Alnylam Pharmaceuticals' active insiders?

Alnylam Pharmaceuticals' insider roster includes Jeffrey Dunn (CEO), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Alnylam Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 52,690 shares worth more than $10,316,756.20. The most recent insider tranaction occured on August, 7th when CMO Pushkal Garg sold 4,166 shares worth more than $766,085.74. Insiders at Alnylam Pharmaceuticals own 1.4% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.

Information on this page was last updated on 8/7/2023.

Yvonne Greenstreet Insider Trading History at Alnylam Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2023Sell4,057$185.85$753,993.4535,216View SEC Filing Icon  
4/27/2023Sell7,615$194.59$1,481,802.8530,332View SEC Filing Icon  
8/6/2021Sell53,064$199.00$10,559,736.00View SEC Filing Icon  
1/12/2021Sell3,125$161.00$503,125.007,945View SEC Filing Icon  
7/9/2020Sell11,236$161.00$1,808,996.0015,759View SEC Filing Icon  
5/5/2020Sell7,811$140.00$1,093,540.0011,070View SEC Filing Icon  
2/10/2020Sell9,892$130.00$1,285,960.0012,458View SEC Filing Icon  
2/7/2020Sell6,250$123.90$774,375.0012,458View SEC Filing Icon  
11/20/2019Sell8,404$105.00$882,420.004,070View SEC Filing Icon  
8/30/2018Sell2,500$120.00$300,000.001,916View SEC Filing Icon  
3/26/2018Sell7,221$136.54$985,955.347,221View SEC Filing Icon  
See Full Table

Yvonne Greenstreet Buying and Selling Activity at Alnylam Pharmaceuticals

This chart shows Yvonne Greenstreet's buying and selling at Alnylam Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $170.04
Low: $170.00
High: $175.03

50 Day Range

MA: $165.94
Low: $151.41
High: $178.96

2 Week Range

Now: $170.04
Low: $148.10
High: $242.97


467,361 shs

Average Volume

519,059 shs

Market Capitalization

$21.34 billion

P/E Ratio


Dividend Yield